GlassScriptPhysician profile
Haitam Buaisha
NPI 1558770743
$6,180.42
in general payments reported to CMS, 2019-2025
16 companies · $1,706 in 2025
The $1,706 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $148 · 2021: $169 · 2022: $337 · 2023: $458 · 2024: $3,186 · 2025: $1,706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,580 · Food and Beverage: $1,770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,580.37 |
| Food and Beverage | $1,770.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $2,658.73 | 2024-2025 | Disposable Distal Attachment, Olympus, Visiglide |
| Boston Scientific Corporation | $1,731.93 | 2019-2025 | Exalt Model D, General - Therapies, Watchman Flx |
| Abbvie INC. | $477.78 | 2019-2025 | Linzess, Viberzi, Creon |
| Gilead Sciences, INC. | $370.36 | 2019-2023 | |
| Janssen Biotech, INC. | $281.69 | 2019-2023 | Stelara, Simponi Aria, Remicade |
| Olympus America INC. | $250.75 | 2021-2025 | Endoclot Phs, Single Use Repositionable Clip, Hanarostent Esophagus Tts(Ccc) |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $169.73 | 2019-2023 | Xifaxan |
| Genzyme Corporation | $58.71 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.65 | 2021-2023 | Entyvio |
| Cook Medical LLC | $32.56 | 2025 | Echotip Insight, Hemospray |
| Ironwood Pharmaceuticals, INC | $28.83 | 2022-2023 | Linzess |
| Regeneron Healthcare Solutions, INC. | $22.79 | 2023 | Dupixent |
| Celgene Corporation | $18.50 | 2023 | Zeposia |
| Aimmune Therapeutics, INC. | $16.17 | 2025 | Vowst |
| Intercept Pharmaceuticals, INC. | $13.23 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $13.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haitam Buaisha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.